無料レポート プレゼントキャンペーン 実施中 : メールサービスに新規登録いただいた方にご用意した無料レポートをご提供

株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙SALE
市場調査レポート

肺動脈性高血圧症 (PAH) 治療薬の世界市場:2017〜2021年

Global Pulmonary Arterial Hypertension (PAH) Drugs Market 2017-2021

発行 TechNavio (Infiniti Research Ltd.) 商品コード 488015
出版日 ページ情報 英文 70 Pages
即納可能
価格
本日の銀行送金レート: 1USD=113.36円で換算しております。
Back to Top
肺動脈性高血圧症 (PAH) 治療薬の世界市場:2017〜2021年 Global Pulmonary Arterial Hypertension (PAH) Drugs Market 2017-2021
出版日: 2017年04月12日 ページ情報: 英文 70 Pages
概要

世界の肺動脈性高血圧症 (PAH) 治療薬の市場規模は、2017〜2021年に3.2%のCAGR (複合年間成長率) で成長する見通しです。

当レポートでは、世界の肺動脈性高血圧症 (PAH) 治療薬の市場について分析し、疾患・製品の概要や市場の基本構造、市場規模の動向 (今後5年間の予測値)、投与経路別・作用機序別・地域別の詳細動向、市場の促進・抑制要因とその影響力、主要企業のプロファイル、今後の市場機会などを調査・推計しております。

第1章 エグゼクティブ・サマリー

第2章 分析範囲

第3章 市場分析の手法

第4章 イントロダクション

  • 市場動向の概略

第5章 肺動脈性高血圧症 (PAH) の概要

第6章 パイプライン分析

第7章 市場環境

  • 市場概要
  • ファイブフォース分析

第8章 投与経路 (RoA) 別の市場区分

  • 経口投与
  • 注射剤
  • 吸入剤

第9章 作用機序 (MoA) 別の市場区分

  • エンドセリン受容体拮抗薬 (ERA)
  • プロスタサクリン類似体
  • PDE (ホスホジエステラーゼ) 阻害剤
  • sGC (可溶性グアニリルシクラーゼ) 刺激薬

第10章 地域区分

  • 南北アメリカ市場
  • 欧州・中東・アフリカ諸国 (EMEA) 市場
  • アジア太平洋地域市場

第11章 意思決定フレームワーク

第12章 促進要因と課題

  • 市場促進要因
  • 主な顧客部門に対する促進要因の影響度
  • 市場の課題
  • 主な顧客部門に対する課題の影響度

第13章 市場の動向

  • 併用療法に対する関心の増大
  • 関心の増大
  • ベンダー間の激しい競争

第14章 ベンダー環境

  • 競争シナリオ

第15章 主要ベンダーの分析

  • Actelion Pharmaceuticals
  • 第一三共
  • GlaxoSmithKline
  • Novartis
  • United Therapeutics
  • その他の有力ベンダー

第16章 付録

  • 略語集
図表
  • Exhibit 01: Categorization of PAH
  • Exhibit 02: Pipeline overview
  • Exhibit 03: Pipeline landscape
  • Exhibit 04: Global PAH drugs market snapshot
  • Exhibit 05: Global PAH drugs market 2016-2021 ($ millions)
  • Exhibit 06: Opportunity analysis of global PAH market 2016
  • Exhibit 07: Five forces analysis
  • Exhibit 08: Market segmentation by RoA
  • Exhibit 09: Global PAH drugs market segmentation by RoA 2016
  • Exhibit 10: Global PAH drugs market segmentation by MoA
  • Exhibit 11: Global ERAs market 2016-2021 ($ millions)
  • Exhibit 12: Global prostacyclin analogs market 2016-2021 ($ millions)
  • Exhibit 13: Global PDE inhibitors market 2016-2021 ($ millions)
  • Exhibit 14: Global PAH sGC stimulators market 2016-2021 ($ million)
  • Exhibit 15: Geographical segmentation of PAH drugs market
  • Exhibit 16: PAH drugs market revenue by geography 2016-2021 (%)
  • Exhibit 17: Market scenario in Americas
  • Exhibit 18: PAH drugs market in Americas 2016-2021 ($ millions)
  • Exhibit 19: Market scenario in EMEA
  • Exhibit 20: PAH drugs market in EMEA 2016-2021 ($ millions)
  • Exhibit 21: Market scenario in APAC
  • Exhibit 22: PAH drugs market in APAC 2016-2021 ($ millions)
  • Exhibit 23: Impact of drivers
  • Exhibit 24: Impact of challenges
  • Exhibit 25: Competitive structure analysis of global PAH drugs market 2016
  • Exhibit 26: Competitive analysis of global PAH drugs market 2016
  • Exhibit 27: Actelion Pharmaceuticals: Key highlights
  • Exhibit 28: Actelion Pharmaceuticals: Strength assessment
  • Exhibit 29: Actelion Pharmaceuticals: Strategy assessment
  • Exhibit 30: Actelion Pharmaceuticals: Opportunity assessment
  • Exhibit 31: DAIICHI SANKYO: Key highlights
  • Exhibit 32: DAIICHI SANKYO: Strength assessment
  • Exhibit 33: DAIICHI SANKYO: Strategy assessment
  • Exhibit 34: DAIICHI SANKYO: Opportunity assessment
  • Exhibit 35: GlaxoSmithKline: Key highlights
  • Exhibit 36: GlaxoSmithKline: Strength assessment
  • Exhibit 37: GlaxoSmithKline: Strategy assessment
  • Exhibit 38: GlaxoSmithKline: Opportunity assessment
  • Exhibit 39: Novartis: Key highlights
  • Exhibit 40: Novartis: Strength assessment
  • Exhibit 41: Novartis: Strategy assessment
  • Exhibit 42: Novartis: Opportunity assessment
  • Exhibit 43: United Therapeutics: Key highlights
  • Exhibit 44: United Therapeutics: Strength assessment
  • Exhibit 45: United Therapeutics: Strategy assessment
  • Exhibit 46: United Therapeutics: Opportunity assessment
目次
Product Code: IRTNTR12459

About Pulmonary Arterial Hypertension (PAH) Drugs

PAH in the arteries, which carry blood from the heart to the lungs, occurs when blood vessels become narrow, making blood flow difficult.

Technavio's analysts forecast the global pulmonary arterial hypertension drugs market to grow at a CAGR of 3.2% during the period 2017-2021.

Covered in this report

The report covers the present scenario and the growth prospects of the global pulmonary arterial hypertension drugs market for 2017-2021. To calculate the market size, the report considers the MoA and the RoA.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA

Technavio's report, Global Pulmonary Arterial Hypertension Drugs Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

  • Actelion Pharmaceuticals
  • DAIICHI SANKYO
  • GlaxoSmithKline
  • Novartis
  • United Therapeutics

Other Prominent Vendors

  • AADi
  • Actelion Pharmaceuticals
  • Aires Pharmaceuticals
  • Arena Pharmaceuticals
  • Asklepion Pharmaceuticals
  • AstraZeneca
  • Bayer Healthcare
  • Berlin Cures
  • BIAL
  • DEKA Research & Development
  • Dong- A ST
  • Eiger BioPharmaceuticals
  • Gilead Sciences
  • Lung Biotechnology
  • Merck
  • Northern Therapeutics
  • Pfizer
  • PhaseBio Pharmaceuticals
  • Radikal Therapeutics
  • Reata Pharmaceuticals
  • SteadyMed Therapeutics
  • Velo Bio

Market driver

  • New disease-modifying therapies
  • For a full, detailed list, view our report

Market challenge

  • Patent expiries of major drugs
  • For a full, detailed list, view our report

Market trend

  • Increased focus on combination therapies
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2021 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Table of Contents

PART 01: Executive summary

PART 02: Scope of the report

PART 03: Research Methodology

PART 04: Introduction

  • Key market highlights

PART 05: An overview of PAH

PART 06: Pipeline analysis

PART 07: Market landscape

  • Market overview
  • Five forces analysis

PART 08: Market segmentation by route of administration (RoA)

  • Oral administration
  • Injectables
  • Inhalation

PART 09: Market segmentation by mechanism of action (MoA)

  • ERAs
  • Prostacyclin analogs
  • PDE inhibitors
  • sGC stimulators

PART 10: Geographical segmentation

  • PAH market in Americas
  • PAH market in EMEA
  • PAH market in APAC

PART 11: Decision framework

PART 12: Drivers and challenges

  • Market drivers
  • Impact of drivers on key customer segments
  • Market challenges
  • Impact of challenges on key customer segments

PART 13: Market trends

  • Increased focus on combination therapies
  • Increase in awareness
  • Intense competition among vendors

PART 14: Vendor landscape

  • Competitive scenario

PART 15: Key vendor analysis

  • Actelion Pharmaceuticals
  • DAIICHI SANKYO
  • GlaxoSmithKline
  • Novartis
  • United Therapeutics
  • Other prominent vendors

PART 16: Appendix

  • List of abbreviations
Back to Top